Clinical Trials
24 trialsNCT03740165 2026-05-04
KEYLYNK-001
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04191135 2026-03-03
KEYLYNK-009
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT03976323 2026-02-25
Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03829319 2026-02-05
LEAP-006
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03635567 2026-02-04
KEYNOTE-826
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03358472 2025-12-03
Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
Incyte Corporation
Phase 3 Completed
NCT03396445 2025-11-05
MK-5890-001
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT02964013 2025-10-14
KEYVIBE-001
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT04716933 2025-09-09
LEAP-006
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT04924101 2025-07-23
KEYNOTE-B99
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT02358031 2025-07-18
MK-3475-048
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04489888 2025-06-19
MK-3475-B10
Merck Sharp & Dohme LLC
Phase 4 Completed
NCT02819518 2024-11-27
KEYNOTE-355
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02775435 2024-10-08
KEYNOTE-407
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03875092 2024-10-01
KEYNOTE-407
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03664024 2024-08-22
KEYNOTE-782
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT03950674 2024-06-10
MK-3475-189
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02735239 2024-03-22
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT03850444 2023-09-18
Keynote 042
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03066778 2022-10-03
KEYNOTE-604
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02549209 2022-03-02
Pembro/Carbo/Taxol in Endometrial Cancer
Big Ten Cancer Research Consortium
Phase 2 Completed
NCT02622074 2020-09-10
KEYNOTE 173
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01704287 2020-05-18
KEYNOTE 002
Merck Sharp & Dohme LLC
Phase 2 Completed